Asendin

Depression, Generalized Anxiety Disorder, Agitation + 4 more

Treatment

20 Active Studies for Asendin

What is Asendin

Amoxapine

The Generic name of this drug

Treatment Summary

Amoxapine is an antidepressant medication that belongs to a class of drugs called tricyclic antidepressants (TCAs). TCAs work by increasing levels of serotonin and norepinephrine, two chemicals in the brain that can improve mood. Amoxapine can be used to treat depression and anxiety, and it may cause sedation in people who are not depressed. Common side effects include blurred vision, dry mouth, constipation, and urinary retention.

Amoxapine

is the brand name

image of different drug pills on a surface

Asendin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Amoxapine

Amoxapine

1992

5

Effectiveness

How Asendin Affects Patients

Amoxapine is an antidepressant drug that works differently than other antidepressants. It has a calming effect, and the way it affects the body is not fully understood. In animals, Amoxapine has been shown to reduce the uptake of certain chemicals (nor-epinephirine and serotonin) and block the effect of dopamine. It does not work by blocking an enzyme like some other antidepressants. Studies suggest that Amoxapine works faster than other types of antidepressants.

How Asendin works in the body

Amoxapine works by blocking the absorption of two brain chemicals, norepinephrine and serotonin.

When to interrupt dosage

The prescribed dosage of Asendin is contingent upon the diagnosed condition, for example Neurotic depression, Psychotic Depression and Agitation. The magnitude of dosage fluctuates, conforming to the technique of delivery (e.g. Oral or Tablet) highlighted in the depicted table.

Condition

Dosage

Administration

Agitation

, 50.0 mg, 25.0 mg, 100.0 mg, 150.0 mg

Tablet, , Oral, Tablet - Oral

Depression

, 50.0 mg, 25.0 mg, 100.0 mg, 150.0 mg

Tablet, , Oral, Tablet - Oral

Generalized Anxiety Disorder

, 50.0 mg, 25.0 mg, 100.0 mg, 150.0 mg

Tablet, , Oral, Tablet - Oral

Mental Depression

, 50.0 mg, 25.0 mg, 100.0 mg, 150.0 mg

Tablet, , Oral, Tablet - Oral

Psychotic Depression

, 50.0 mg, 25.0 mg, 100.0 mg, 150.0 mg

Tablet, , Oral, Tablet - Oral

Mental Depression

, 50.0 mg, 25.0 mg, 100.0 mg, 150.0 mg

Tablet, , Oral, Tablet - Oral

Neurotic depression

, 50.0 mg, 25.0 mg, 100.0 mg, 150.0 mg

Tablet, , Oral, Tablet - Oral

Warnings

Asendin Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Asendin.

Common Asendin Drug Interactions

Drug Name

Risk Level

Description

Acepromazine

Major

Amoxapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Amoxapine is combined with Aclidinium.

Alfuzosin

Major

Amoxapine may increase the hypotensive activities of Alfuzosin.

Amisulpride

Major

Amoxapine may increase the antipsychotic activities of Amisulpride.

Aripiprazole

Major

Amoxapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.

Asendin Toxicity & Overdose Risk

Taking too much of the medication amoxapine can lead to seizures, coma, and acidosis. In some cases, kidney failure may occur two to five days after an overdose. In rare cases, kidney failure may be accompanied by muscle breakdown, pain, and discolored urine.

image of a doctor in a lab doing drug, clinical research

Asendin Novel Uses: Which Conditions Have a Clinical Trial Featuring Asendin?

819 clinical trials are in progress to ascertain the potential of Asendin to ameliorate Neurotic Depression, Agitation and Mental Depression.

Condition

Clinical Trials

Trial Phases

Psychotic Depression

0 Actively Recruiting

Generalized Anxiety Disorder

181 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 4, Phase 1, Phase 3

Mental Depression

0 Actively Recruiting

Mental Depression

0 Actively Recruiting

Neurotic depression

0 Actively Recruiting

Depression

305 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Agitation

3 Actively Recruiting

Phase 2, Phase 3, Not Applicable

Asendin Reviews: What are patients saying about Asendin?

5

Patient Review

6/9/2009

Asendin for Depression

I was on this medication for 3 years and it did help me, though I'm not sure why my doctor decided to take me off of it.

5

Patient Review

7/4/2017

Asendin for Anxiousness associated with Depression

I find amaoxopine to be much more effective for anxiety than Benzodiazepines, which build up a tolerance over time. I feel so much better now that I've switched.

3.3

Patient Review

12/20/2010

Asendin for Depression

I'm still not entirely sure if this is the right medication for me. I'm looking for an antidepressant that helps with dopamine and norepinephrine production, since SSRIs don't seem to work well with my brain chemistry.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about asendin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long does amoxapine take to work?

"This medication doesn't work immediately. It could take up to two weeks for you to experience the full benefits."

Answered by AI

What is asendin used for?

"This medication is used to treat depression by restoring the balance of natural chemicals (neurotransmitters) in the brain."

Answered by AI

Is amoxapine an antipsychotic drug?

"Although it is marketed as an antidepressant, amoxapine's in-vitro profile, receptor occupancy and preclinical effects are very similar to those of atypical antipsychotics. Amoxapine has also shown efficacy as an atypical antipsychotic in open trials."

Answered by AI

Can amoxapine make you sleepy?

"Amoxapine can cause drowsiness, so it is best to take it at night, especially when you first start taking it. In the beginning, you might need to take smaller doses multiple times a day so your body can get used to the medication."

Answered by AI

Clinical Trials for Asendin

Image of University of California, Los Angeles in Los Angeles, United States.

Digital Therapy for Postpartum Depression

18+
Female
Los Angeles, CA

The purpose of this study is to determine if the addition of digital sensing data collected from phones and watches during the early stages of perinatal depression (PND) treatment can better predict treatment outcomes than using self-reported symptoms alone.STAND for PND: The UCLA Depression Grand Challenge (DGC) has previously developed a technology-assisted, scalable therapy system called STAND (Screening and Treatment for ANxiety and Depression) for perinatal depression (PND) and has demonstrated in an initial randomized clinical trial that this treatment intervention to be as effective as psychiatrist delivered care for PND. In this study, the investigators will administer STAND for PND for up to 12 weeks as part of study participation. There will be no comparison between our treatment intervention and a treatment as usual condition, as this is not a trial of efficacy. In the STAND for PND treatment model, women with moderate symptoms will be routed to coach-guided, digital cognitive behavioral therapy (CBT) tailored to PND, which has been demonstrated to be an effective treatment approach for PND. Women with severe depression or suicidality will be routed to clinician delivered CBT, with pharmacotherapy as needed, with both CBT and pharmacotherapy demonstrated to be effective treatment approaches for PND. Symptoms will be regularly monitored throughout the intervention period. Digital Sensing in Depression: The DGC also has substantial experience in large-scale longitudinal digital sensing studies, and experience identifying associations between self-report or clinical ratings of depressive symptoms and digital sensing features, including in pregnant and postpartum women. Digital Sensing in a STAND for PND study: In our previous STAND for PND study, the investigators did not include digital sensing. In this next phase of our research program, the investigators will collect digital sensing data from phones and watches during the first four weeks of study participation. The investigators will enroll up to 250 women during their last trimester or who are in the postpartum period to participate in the 12-week study, which includes treatment provided through the STAND for PND program of care and during which the investigators will obtain 4-weeks of digital sensing data.The investigators will be testing whether behaviors measures through digital sensing (i.e., digital features) in combination with self-reported depression symptoms will better predict treatment outcomes than the self-reported depression symptoms alone. The investigators are testing the hypothesis that prospective longitudinal assessments using digital devices will enhance our ability to predict outcomes of STAND-PND.This project is part of a larger program of research that aims to improve clinical decision-making for PND by establishing a clinical care model for PND that fully integrates digital sensing with digital therapy. An additional objective of this program of research is to target low-income mothers from populations that have had limited access to mental healthcare, given that this population is particularly vulnerable to the impact of PND.

Waitlist Available
Has No Placebo

University of California, Los Angeles

Nelson Freimer, MD

Image of Imperial Valley College in Imperial, United States.

Cognitive Behavioral Therapy for Mental Health

18+
All Sexes
Imperial, CA

The goal of this study is to understand why certain treatments help people reduce repetitive negative thinking (RNT), which is common in many mental health problems. We want to: 1. Figure out what actually causes repetitive negative thinking to decrease when people use cognitive-behavioral therapy (CBT). 2. Find out which parts of RNT-focused CBT are the most important - the parts that truly make a difference in reducing RNT. The main result we will look at is how much a person's repetitive negative thought patterns change from the start of the study to the end of treatment (16 weeks). We will measure this using the Perseverative Thinking Questionnaire at baseline and week 16.

Waitlist Available
Has No Placebo

Imperial Valley College

Have you considered Asendin clinical trials?

We made a collection of clinical trials featuring Asendin, we think they might fit your search criteria.
Go to Trials
Image of The Korean Association of West Florida in Tampa, United States.

Mobile App Mindfulness for Mental Health

18+
All Sexes
Tampa, FL

The goal of this clinical trial (single-arm pilot trial) is to learn whether a mobile application-based mindfulness intervention can improve mental health outcomes in older Korean immigrants aged 60 years and older. The main questions it aims to answer are whether the 8-week mobile app-based mindfulness intervention is feasible and acceptable, as indicated by recruitment, retention, and adherence rates, and whether participation in the intervention leads to improvements in positive psychological well-being (e.g., positive affect, optimism, life engagement, and mindfulness) and reductions in adverse mental health outcomes (e.g., anxiety, depressive symptoms, and perceived stress). Participants will complete baseline and post-intervention assessments, receive training on how to use the mobile mindfulness application, engage with the app for approximately 8 weeks (recommended 10-15 minutes per day), and participate in weekly check-ins to support engagement and address any challenges encountered during the intervention.

Waitlist Available
Has No Placebo

The Korean Association of West Florida (+1 Sites)

Soonhyung Kwon

Image of Brown University in Providence, United States.

Mindfulness-Based Intervention for Mental Health

18 - 24
All Sexes
Providence, RI

The goal of this clinical trial (single-arm feasibility study) is to examine the feasibility, acceptability, and preliminary efficacy of a mindfulness-based, app-delivered intervention to address mental health and emotion regulation challenges in young adults with early life adversities (ELAs). The main questions it aims to answer is: \- Will young adults find the Growth, Empowerment, and Mindfulness (GEM) intervention to be both feasible and acceptable, as demonstrated by participants' engagement and quantitative/qualitative feedback? Additionally, it aims to answer: * Will GEM intervention demonstrate preliminary efficacy in improving outcome measures including depression, anxiety? * Are improvements in mindfulness and sleep, as well as reductions in rumination, mechanisms of action underlying the improvements in psychological and behavioral outcomes of the intervention? Participants will be asked to: * participate in GEM, which integrates app-based intervention content, formal and informal mindfulness practices, weekly Zoom group sessions, and ecological momentary intervention (EMI) delivery * complete baseline, post-intervention, and 3-month follow-up assessments * complete weekly assessments and daily ecological momentary assessments (EMAs) during the intervention delivery * wear Fitbit for researchers to collect sleep-related data

Waitlist Available
Has No Placebo

Brown University

Shufang Sun, PhD

Image of Michael E. DeBakey VA Medical Center, Houston, TX in Houston, United States.

Behavioral Activation-Guided Self-Help for Depression

18+
All Sexes
Houston, TX

Symptoms of depression are highly prevalent among Veterans. However, fewer than 30% of individuals with these symptoms receive any psychotherapy in the Veterans Health Administration (VHA). This is due to many factors, which may include provider availability and patient preferences. Guided self-help (GSH), which involves coaching sessions with patients who are following a fully developed self-help program, has the potential to increase access to care for these Veterans, particularly if implemented within a stepped care model of mental health treatment delivery and if delivered by a diverse set of providers. The VHA's primary care-mental health integration (PCMHI) service, which focuses on short courses of care for mild to moderate symptoms, may be an ideal place in which to deploy GSH. The current project seeks conduct a pilot randomized trial of a GSH program for depression adapted for PCMHI based on behavioral activation.

Waitlist Available
Has No Placebo

Michael E. DeBakey VA Medical Center, Houston, TX

Maribel Plasencia, BA MS PhD

Image of Vanderbilt University Medical Center in Nashville, United States.

Cognitive Training + tDCS for Depression

18+
All Sexes
Nashville, TN

The goal of this clinical trial is to learn if a combination of non-drug treatments works to benefit memory, thinking, and brain functioning in older individuals with recurrent depression. The non-drug approaches the investigators are studying include transcranial direct current stimulation (tDCS) and computerized cognitive training. tDCS uses small currents of electricity on the forehead to potentially stimulate your brain's ability to process and learn. Computerized cognitive training uses tablet games to improve memory and thinking. In this study, two different cognitive training programs are being investigated, both of which are stimulating and designed to engage brain activity. One that is believed to be a specific treatment for depression, while the other provides extra stimulation for the brain that is non-specific. Two different tDCS parameters - active stimulation and sham (or placebo) stimulation - are also being investigated. Participants will be randomized to one of three study groups: 1. Depression cognitive training treatment with active brain stimulation 2. Depression cognitive training treatment with sham brain stimulation 3. Non-specific cognitive training treatment with sham brain stimulation The main questions this clinical trial aims to answer are: * Does "depression cognitive training treatment with active brain stimulation" benefit thinking and memory more so than the other treatments? * Does "depression cognitive training treatment with active brain stimulation" benefit brain functioning more so than the other treatments? Participants will: * Complete several baseline and post-intervention visits at the research center for checkups and tests over the course of 3-4 months. * Visit the research center daily for 4 weeks to complete their assigned treatment.

Waitlist Available
Has No Placebo

Vanderbilt University Medical Center

Have you considered Asendin clinical trials?

We made a collection of clinical trials featuring Asendin, we think they might fit your search criteria.
Go to Trials
Image of UF World Equestrian Center in Ocala, United States.

ONE-D TMS + D-Cycloserine for Depression and Concussion

18 - 65
Female
Ocala, FL

Concussion and depression have long been recognized to be intertwined pathologies.1-3 Although female athletes are more likely to suffer from mental health symptoms than males athletes following a concussion,2 research in this area has been largely biased toward males.4 Recently functional MRI (fMRI) studies5 in concussed athletes have established that there are patterns of local alterations in neural connectivity in the frontal cortex that demonstrate anatomic congruency with transcranial magnetic stimulation (TMS) studies that mapped alternations in neural connectivity to functional and somatic symptoms.6 Thus, there is potential that TMS treatment could decrease both symptom profiles, revolutionizing comorbid treatment options. Possible Benefits: Previous studies have showed a 70% remission rate for depression symptoms. It is possible that participants could have improvement in depressive or concussive symptoms after the ONE-D TMS treatment.

Phase 2 & 3
Waitlist Available

UF World Equestrian Center

Sara Gould, MD

Image of Southern Methodist University in Dallas, United States.

Positive Affect Treatment for Depression and Anxiety

18 - 65
All Sexes
Dallas, TX

The purpose of this study is to evaluate the feasibility and acceptability of Positive Affect Treatment (PAT) in a Spanish-speaking population. PAT is a psychotherapy specifically aimed at enhancing reward sensitivity in individuals with low positive affect (a core feature of anhedonia) in the context of depression or anxiety. Target enrollment is 12 participants with low positive affect and depression or anxiety and impaired functioning, between the ages of 18 and 65 years. Participants will complete psychiatric assessments and self-report questionnaires as part of the study. The total length of participation is around 4 months.

Waitlist Available
Has No Placebo

Southern Methodist University

Alicia E Meuret, Ph.D.

Image of CVT in Centennial, United States.

Treatment for Anxiety Disorders

18 - 70
All Sexes
Centennial, CO

The goal of this hybrid implementation-effectiveness study is to learn about the effectiveness and appropriateness of "Trauma-Informed and Culturally-Responsive Integrated Massage Therapy" (TCI-Massage) for torture and war trauma survivors. The study aims are: • Examine the uptake of TCI-Massage within CVT by assessing key implementation science outcomes of acceptability and appropriateness among refugees and asylum seekers from diverse cultural backgrounds. • Examine the integration of massage therapy into the current psychosocial care model used at CVT. • Examine the effectiveness of TCI-Massage for torture and war trauma survivors to reduce distress (mental health symptoms, chronic pain, and HRV) and improve coping (interoceptive awareness and social functioning). Treatment group participants will participate in psychosocial care services + TCI-Massage, which the control group will only participate in psychosocial care services

Waitlist Available
Has No Placebo

CVT

Have you considered Asendin clinical trials?

We made a collection of clinical trials featuring Asendin, we think they might fit your search criteria.
Go to Trials